Photodynamic therapy for focal ablation of the prostate

World Journal of Urology

Volumn 28, Issue 5, 2010, Pages 571-576

  Arumainayagam, Nimalan ^a   Moore, C M ^a   Ahmed, Hashim U ^a   Emberton, M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Focal treatment; Photodynamic therapy; Prostate cancer

Indexed keywords

LUTETIUM TEXAPHYRIN; MESOPORPHYRIN; METALLOPORPHYRIN; PHOTOFRIN II; PHOTOSENSITIZING AGENT; TEMOPORFIN;

ARTICLE; HUMAN; MALE; PHOTOCHEMOTHERAPY; PROSTATE TUMOR; TREATMENT OUTCOME;

DIHEMATOPORPHYRIN ETHER; HUMANS; MALE; MESOPORPHYRINS; METALLOPORPHYRINS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77957116446     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0554-2     Document Type: Article

References (27)

1. Wormald R, Evans J, Smeeth L, Henshaw K (2007) Photodynamic therapy for age-related macular degeneration. Cochrane Database Syst Rev 18(3): CD002030.
2. Lou PJ, Jager HR, Jones L, Theodossy T, Bown SG, Hopper C (2004) Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 91(3): 441-446.
3. Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P et al (2002) Photodynamic therapy for cancer of the pancreas. Gut 50(4): 549-557.
4. Selman SH, Keck RW, Hampton JA (1996) Transperineal photodynamic ablation of the canine prostate. J Urol 156: 258-260.
5. Selman SH, Albrecht D, Keck RW, Brennan P, Kondon S (2001) Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate. J Urol 165: 1795-1801.
6. Hsi RA, Kapatkin A, Strandberg J, Zhu T, Vulcan T, Solonencko M et al (2001) Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res 7(3): 651-660.
7. Lee LK, Whitehurst C, Chen Q, Pantelides ML, Hetzel FW, Moore JV (1997) Interstitial photodynamic therapy in the canine prostate. Br J Urol 80: 898-902.
8. Chang SC, Buonaccorsi GA, MacRobert AJ, Bown SG (1997) Interstitial photodynamic therapy in the canine prostate with disulfonated aluminium phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate 32: 89-98.
9. Chang SC, Buonaccorsi GA, MacRobert AJ, Bown SG (1996) Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Int J Cancer 67: 555-562.
10. Windhal T, Andersson SO, Lofgren L (1990) Photodynamic therapy of localised prostate cancer. Lancet 336: 1139.
11. Nathan TR, Whitelaw DE, Chang SC, Lees WR, Ripley PM, Payne H et al (2002) Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase 1 study. J Urol 168: 1427-1432.
12. Moore CM, Nathan TR, Lees WR, Freeman A, Emberton M, Bown SG (2006) Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med 385: 356-363.
13. Zaak D, Sroka R, Hoppner M, Khoder W, Reich O, Tritschler S et al (2003) Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer-preliminary results. Med Laser Appl 18: 91-95.
14. Verigos K, Stripp DC, Mick R, Zhu TC, Whittington R, Smith D et al (2006) Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 25: 373-387.
15. Patel H, Mick R, Finlay J, Rickter E, Cengel CE, Malkowicz S et al (2008) Motexifen lutetium photodynamic therapy of prostate cancer: Short and long-term effects on prostate specific antigen. Clin Cancer Res 14: 4869-4876.
16. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA et al (2007) Vascular-targeted photodynamic therapy with palladium bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 178: 1974-1979.
17. Haider MA, Davidson SR, Kale AV, Weersink RA, Evans AJ, Toi A et al (2007) Prostate gland MR imaging appearance after vascular targeted photodynamic therapy with palladium bacteriopheophorbide. Radiology 244(1): 196-204.
18. Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR et al (2008) Vascular-targeted photodynamic therapy (padoporfin WST-09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 102(5): 556-562.
19. Pendse D, Moore CM, Arumainayagam N, Mosse CA, Allen C, Bown SG et al (2009) WST-09 mediated photodynamic therapy for prostate cancer (Abstract).
20. ® soluble (padeliporfin) second generation vascular targeted photodynamic therapy (VTP) for prostate cancer: safety and feasibility. EAU Annual Meeting 2010 (Abstract).
21. Svensson T, Alerstam E, Einarsdottir M, Svanberg K, Andersson-Engels S (2008) Towards accurate in vivo spectroscopy of the human prostate. J Biophotonics 1(3): 200-203.
22. Johansson A, Axelsson J, Andersson-Engels S, Swartling J (2007) Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate. Med Phys 34(11): 4309-4321.
23. Atri M, Gertner MR, Haider MA, Weersink RA, Trachtenberg J (2009) Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can Urol Assoc J 3(2): 125-130.
24. Curnow A, MacRobert AJ, Bown SG (2006) Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med 38(4): 325-331.
25. Sharman WM, van Lier JE, Allen CM (2004) Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 56: 53-76.
26. Vrouenraets MB, Visser GW, Stigter M, Oppelaar H, Snow GB, van Dongen GA (2002) Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro. Int J Cancer 98(5): 793-798.
27. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller JW (2004) Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovasculaturization mediated by a homing peptide to vascular endothelial growth factor receptor-s2. Arch Ophthalmol 122(7): 1002-1011.